, Plaquettes <, vol.100, issue.7, p.90

, TP (%), vol.77, pp.61-60

. Bilirubine, , vol.41, pp.60-81

A. , , vol.31, p.4

T. Akinyemiju, S. Abera, M. Ahmed, N. Alam, M. A. Alemayohu et al., The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level, JAMA Oncol. déc, vol.3, issue.12, pp.1683-91, 2017.

H. B. El-serag, Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma, Gastroenterology. mai, vol.142, issue.6, pp.1264-1273, 2012.

F. Binder-foucard, N. Bossard, P. Delafosse, A. Belot, A. Woronoff et al., Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors, Rev DÉpidémiologie Santé Publique. 1 avr, vol.62, issue.2, pp.95-108, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915012

R. De-angelis, M. Sant, M. P. Coleman, S. Francisci, P. Baili et al., Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study, Lancet Oncol. 1 janv, vol.15, issue.1, pp.23-34, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915077

B. Cadier, J. Bulsei, P. Nahon, O. Seror, A. Laurent et al., Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States, Hepatology, vol.65, issue.4, pp.1237-1285, 2017.

J. F. Blanc, J. C. Barbare, A. S. Baumann, V. Boige, K. Boudjema et al., Thésaurus National de Cancérologie Digestive, 2019.

P. R. Galle, A. Forner, J. M. Llovet, V. Mazzaferro, F. Piscaglia et al., Clinical Practice Guidelines: Management of hepatocellular carcinoma, J Hepatol. juill, vol.69, issue.1, pp.182-236, 2018.

J. K. Heimbach, L. M. Kulik, R. S. Finn, C. B. Sirlin, M. M. Abecassis et al., AASLD guidelines for the treatment of hepatocellular carcinoma: Heimbach et al, Hepatology. janv, vol.67, issue.1, pp.358-80, 2018.

J. M. Llovet, P. Hilgard, A. C. De-oliveira, A. Forner, S. Zeuzem et al., Sorafenib in Advanced Hepatocellular Carcinoma, N Engl J Med, vol.13, 2008.

A. Cheng, Y. Kang, Z. Chen, C. Tsao, S. Qin et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial, Lancet Oncol. 1 janv, vol.10, issue.1, pp.25-34, 2009.

J. Bruix, S. Qin, M. P. Granito, A. Huang, Y. Bodoky et al., Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, vol.389, pp.56-66, 2017.

M. Reig, J. Rimola, F. Torres, A. Darnell, C. Rodriguez-lope et al., Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design: HEPATOLOGY, REIG ET AL. Hepatology. déc, vol.00, issue.X, pp.2023-2054, 2013.

S. Ogasawara, T. Chiba, Y. Ooka, E. Suzuki, N. Kanogawa et al., Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib, Invest New Drugs. avr, vol.34, issue.2, pp.255-60, 2016.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, vol.68, issue.6, pp.394-424, 2018.

Z. Liu, Y. Jiang, H. Yuan, Q. Fang, N. Cai et al., The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention, J Hepatol. 1 avr, vol.70, issue.4, pp.674-83, 2019.

N. Goutté, P. Sogni, N. Bendersky, J. C. Barbare, B. Falissard et al., Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country, J Hepatol. 1 mars, vol.66, issue.3, pp.537-581, 2017.

G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato, Hepatocellular carcinoma in cirrhosis: Incidence and risk factors, Gastroenterology, vol.127, issue.5, pp.35-50, 2004.

G. N. Ioannou, M. F. Splan, N. S. Weiss, G. B. Mcdonald, L. Beretta et al., Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis, Clin Gastroenterol Hepatol. 1 août, vol.5, issue.8, pp.938-945, 2007.

J. D. Yang, W. R. Kim, R. Coelho, T. A. Mettler, J. T. Benson et al., Cirrhosis is Present in Most Patients with Hepatitis B and Hepatocellular Carcinoma, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. janv, vol.9, issue.1, pp.64-70, 2011.

C. Chen, Y. , H. Su, J. Jen, C. You et al., Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level, JAMA. 4 janv, vol.295, issue.1, pp.65-73, 2006.

C. Sun, D. Wu, C. Lin, S. Lu, S. You et al., Incidence and Cofactors of Hepatitis C Virus-related Hepatocellular Carcinoma: A Prospective Study of 12,008 Men in Taiwan, Am J Epidemiol. 15 avr, vol.157, issue.8, pp.674-82, 2003.

J. D. Yang and L. R. Roberts, Hepatocellular carcinoma: a global view, Nat Rev Gastroenterol Hepatol. août, vol.7, issue.8, pp.448-58, 2010.

M. M. Hassan, L. Hwang, C. J. Hatten, M. Swaim, D. Li et al., Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus, Hepatology, vol.36, issue.5, pp.1206-1219, 2002.

Z. M. Younossi, M. Otgonsuren, L. Henry, C. Venkatesan, A. Mishra et al., Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from, Hepatol Baltim Md. déc, vol.62, issue.6, pp.1723-1753, 2004.

F. Kanwal, J. R. Kramer, Z. Duan, X. Yu, D. White et al., Trends in the Burden of Non-alcoholic Fatty Liver Disease in a US Cohort of Veterans, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. févr, vol.14, issue.2, pp.301-309, 2016.

F. Z. Khan, R. B. Perumpail, R. J. Wong, and A. Ahmed, Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma, World J Hepatol. 28 août, vol.7, issue.18, pp.2155-61, 2015.

B. Charrez, L. Qiao, and L. Hebbard, Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play, World J Gastroenterol. 28 févr, vol.22, issue.8, pp.2494-502, 2016.

K. K. Tsilidis, J. C. Kasimis, D. S. Lopez, E. E. Ntzani, and J. Ioannidis, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies, BMJ. 2 janv, vol.350, p.7607, 2015.

, Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis -Wang -2012 -Diabetes/Metabolism Research and Reviews -Wiley Online Library

S. Schlesinger, K. Aleksandrova, T. Pischon, M. Jenab, V. Fedirko et al., Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort, Ann Oncol. sept, vol.24, issue.9, pp.2449-55, 2013.

E. E. Calle, C. Rodriguez, K. Walker-thurmond, and M. J. Thun, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med. 24 avr, vol.348, issue.17, pp.1625-1663, 2003.

C. Ellervik, H. Birgens, A. Tybjaerg-hansen, and B. G. Nordestgaard, Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatol Baltim Md, vol.46, pp.1071-80, 2007.

M. Elmberg, R. Hultcrantz, A. Ekbom, L. Brandt, S. Olsson et al., Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives, Gastroenterology. déc, vol.125, issue.6, pp.1733-1774, 2003.

E. J. Carey, A. H. Ali, and K. D. Lindor, Primary biliary cirrhosis. The Lancet, vol.386, pp.1565-75, 2015.

P. J. Trivedi, W. J. Lammers, A. Buuren-hr-van,-parés, A. Floreani, and H. Janssen, Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study, Gut. 1 févr, vol.65, issue.2, pp.321-330, 2016.

J. A. Marrero, R. J. Fontana, S. Fu, H. S. Conjeevaram, G. L. Su et al., Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma, J Hepatol. 1 févr, vol.42, issue.2, pp.218-242, 2005.

F. Bravi, A. Tavani, C. Bosetti, P. Boffetta, L. Vecchia et al., Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP, vol.26, issue.5, pp.368-77, 2017.

M. Sherman, Surveillance for hepatocellular carcinoma, Best Pract Res Clin Gastroenterol, vol.28, issue.5, pp.783-93, 2014.

A. Forner, M. Reig, and J. Bruix, Hepatocellular carcinoma. The Lancet, vol.31, pp.1301-1315, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01134844

R. Vilana, A. Forner, L. Bianchi, Á. García-criado, J. Rimola et al., Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound, Hepatology. juin, vol.51, issue.6, pp.2020-2029, 2010.

, Asian Pacific Journal of Cancer Prevention

D. Sur,

A. Forner, R. Vilana, C. Ayuso, L. Bianchi, M. Solé et al., Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology. 10 déc, vol.47, issue.1, pp.97-104, 2007.

, The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis

A. Z. Kielar, V. Chernyak, M. R. Bashir, R. K. Do, K. J. Fowler et al., An update: LI-RADS 2017: An update, J Magn Reson Imaging. juin, vol.47, issue.6, pp.1459-74, 2017.

J. Bruix and M. Sherman, Management of hepatocellular carcinoma: An update, Hepatol Baltim Md. mars, vol.53, issue.3, pp.1020-1022, 2011.

K. M. Olthoff, A. Forner, S. Hübscher, and J. Fung, What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc, vol.17, pp.26-33, 2011.

K. Okuda, H. Obata, Y. Nakajima, T. Ohtsuki, N. Okazaki et al., Prognosis of Primary Hepatocellular Carcinoma, Hepatology, vol.4, issue.S1, pp.3-6, 1984.

, The Cancer of the Liver Italian Program (Clip) Investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients, Hepatology, vol.28, issue.3, pp.751-756, 1998.

J. M. Llovet, C. Brú, and J. Bruix, Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification, Semin Liver Dis, vol.19, issue.3, pp.329-367, 1999.

S. Chevret, J. C. Trinchet, D. Mathieu, A. A. Rached, M. Beaugrand et al., A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire, J Hepatol. juill, vol.31, issue.1, pp.133-174, 1999.

T. Leung, A. Tang, B. Zee, W. Y. Lau, P. Lai et al., Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system, Cancer, vol.94, issue.6, pp.1760-1769, 2002.

M. Kudo, H. Chung, S. Haji, Y. Osaki, H. Oka et al., Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score, Hepatology, vol.40, issue.6, pp.1396-405, 2004.

R. Tateishi, H. Yoshida, S. Shiina, H. Imamura, K. Hasegawa et al., Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients, Gut. mars, vol.54, issue.3, pp.419-444, 2005.

T. Yau, V. Tang, T. Yao, S. Fan, C. Lo et al., Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma, Gastroenterology. 1 juin, vol.146, issue.7, pp.1691-1700, 2014.

P. J. Johnson, S. Berhane, C. Kagebayashi, S. Satomura, M. Teng et al., Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade, J Clin Oncol. 20 févr, vol.33, issue.6, pp.550-558, 2015.

K. Lim, P. Chow, J. C. Allen, F. J. Siddiqui, E. Chan et al., Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria, BJS, vol.99, issue.12, pp.1622-1631, 2012.

M. Samuel, P. Chow, E. C. Shih-yen, D. Machin, and K. Soo, Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev, 2009.

V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti et al., Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis


F. Y. Yao, L. Ferrell, N. M. Bass, J. J. Watson, P. Bacchetti et al., Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival, Hepatology, vol.33, issue.6, pp.1394-403, 2001.

V. Mazzaferro, J. M. Llovet, R. Miceli, S. Bhoori, M. Schiavo et al., Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol. 1 janv, vol.10, issue.1, pp.35-43, 2009.

C. Duvoux, F. Roudot-thoraval, T. Decaens, F. Pessione, H. Badran et al., Liver Transplantation for Hepatocellular Carcinoma: A Model Including ?-Fetoprotein Improves the Performance of Milan Criteria, Gastroenterology, vol.143, issue.4, pp.986-994, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00865368

Y. K. Cho, J. K. Kim, M. Y. Kim, H. Rhim, and J. K. Han, Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology, vol.49, issue.2, pp.453-462, 2009.

G. Germani, M. Pleguezuelo, K. Gurusamy, T. Meyer, G. Isgrò et al., Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis, J Hepatol. 1 mars, vol.52, issue.3, pp.380-388, 2010.

J. Yu, X. Yu, Z. Han, Z. Cheng, F. Liu et al., Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial, Gut. juin, vol.66, issue.6, pp.1172-1175, 2017.

A. Cucchetti, F. Piscaglia, M. Cescon, A. Colecchia, G. Ercolani et al., Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma, J Hepatol. 1 août, vol.59, issue.2, pp.300-307, 2013.

J. M. Llovet, M. I. Real, X. Montaña, R. Planas, S. Coll et al., Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet, vol.359, pp.1734-1743, 2002.

C. Lo, N. H. Tso, W. Liu, C. Lam, C. Poon et al., Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology. 1 mai, vol.35, issue.5, pp.1164-71, 2002.

C. Cammà, F. Schepis, A. Orlando, M. Albanese, L. Shahied et al., Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials, Radiology. 1 juill, vol.224, issue.1, pp.47-54, 2002.

J. M. Llovet and J. Bruix, Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival, Hepatology, vol.37, issue.2, pp.429-471, 2003.

R. Salem, R. J. Lewandowski, M. F. Mulcahy, A. Riaz, R. K. Ryu et al., Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes, Gastroenterology. 1 janv, vol.138, issue.1, pp.52-64, 2010.

V. Mazzaferro, C. Sposito, S. Bhoori, R. Romito, C. Chiesa et al., Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study, Hepatology, vol.57, issue.5, pp.1826-1863, 2013.

B. Sangro, L. Carpanese, R. Cianni, R. Golfieri, D. Gasparini et al., Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation, Hepatology, vol.54, issue.3, pp.868-78, 2011.

V. Vilgrain, H. Pereira, E. Assenat, B. Guiu, A. D. Ilonca et al., Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol. 1 déc, vol.18, issue.12, pp.1624-1660, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01727346

P. Chow, M. Gandhi, S. Tan, M. W. Khin, A. Khasbazar et al., Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma, J Clin Oncol. 2 mars, vol.36, issue.19, pp.1913-1934, 2018.

R. Salem, A. C. Gordon, S. Mouli, R. Hickey, J. Kallini et al., Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology. déc, vol.151, issue.6, pp.1155-1163, 2016.

J. H. Kwon, S. H. Bae, J. Y. Kim, B. O. Choi, H. S. Jang et al., Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer, BMC Cancer. 3 sept, vol.10, p.475, 2010.

A. Bujold, C. A. Massey, J. J. Kim, J. Brierley, C. Cho et al., Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma, J Clin Oncol. 1 avr, vol.31, issue.13, pp.1631-1640, 2013.

D. L. Andolino, C. S. Johnson, M. Maluccio, P. Kwo, A. J. Tector et al., Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma, Int J Radiat Oncol ? Biol ? Phys, vol.15, issue.4, pp.447-53, 2011.

P. Merle, F. Mornex, and C. Trepo, Innovative therapy for hepatocellular carcinoma: Three-dimensional high-dose photon radiotherapy, Cancer Lett. 1 déc, vol.286, issue.1, pp.129-162, 2009.

P. J. Johnson, S. Qin, J. Park, R. Poon, R. Philip et al., Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study, J Clin Oncol. 26 août, vol.31, issue.28, pp.3517-3541, 2013.

C. Cainap, S. Qin, W. Huang, I. J. Chung, H. Pan et al., Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial, J Clin Oncol. 10 janv, vol.33, issue.2, pp.172-181, 2015.

A. Cheng, Y. Kang, D. Lin, J. Park, M. Kudo et al., Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial, J Clin Oncol, vol.31, issue.32, pp.4067-75, 2013.

A. X. Zhu, O. Rosmorduc, T. Evans, P. J. Ross, A. Santoro et al., SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma, J Clin Oncol. 20 févr, vol.33, issue.6, pp.559-66, 2015.

J. Jouve, T. Lecomte, O. Bouché, E. Barbier, F. K. Akouz et al., Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma, J Hepatol, vol.21, issue.2019

J. M. Llovet, T. Decaens, J. Raoul, E. Boucher, M. Kudo et al., Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study, J Clin Oncol, vol.31, issue.28, pp.3509-3525, 2013.

A. X. Zhu, M. Kudo, E. Assenat, S. Cattan, Y. Kang et al., Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib: The EVOLVE-1 Randomized Clinical Trial, JAMA. 2 juill, vol.312, issue.1, p.57, 2014.

L. Rimassa, E. Assenat, M. Peck-radosavljevic, M. Pracht, V. Zagonel et al., Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study, Lancet Oncol. 1 mai, vol.19, issue.5, pp.682-93, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02337178

A. X. Zhu, J. O. Park, B. Ryoo, Y. , C. Poon et al., Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol. juill, vol.16, issue.7, pp.859-70, 2015.

G. K. Abou-alfa, T. Meyer, A. Cheng, A. B. El-khoueiry, L. Rimassa et al., Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, N Engl J Med. 5 juill, vol.379, issue.1, pp.54-63, 2018.

M. Kudo, R. S. Finn, S. Qin, K. Han, K. Ikeda et al., Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial, The Lancet. mars, vol.391, pp.1163-73, 2018.

A. X. Zhu, Y. Kang, Y. , C. Finn, R. S. Galle et al., Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased ?-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol. 1 févr, vol.20, issue.2, pp.282-96, 2019.

L. Gong, M. M. Giacomini, C. Giacomini, M. L. Maitland, R. B. Altman et al., PharmGKB summary: sorafenib pathways, Pharmacogenet Genomics, vol.27, issue.6, pp.240-246, 2017.

G. K. Abou-alfa, L. Schwartz, S. Ricci, D. Amadori, A. Santoro et al., Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma, J Clin Oncol. 10 sept, vol.24, issue.26, pp.4293-300, 2006.

V. Boige, J. Barbare, and O. Rosmorduc, Utilisation du sorafénib (Nexavar®) dans le traitement du carcinome hépatocellulaire : recommandations Prodige Afef, Gastroentérologie Clin Biol. 1 janv, vol.32, issue.1, pp.3-7, 2008.

J. A. Marrero, M. Kudo, A. P. Venook, S. Ye, J. Bronowicki et al., Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study, J Hepatol. 1 déc, vol.65, issue.6, pp.1140-1147, 2016.

A. Villanueva and . Hepatocellular-carcinoma, N Engl J Med. 11 avr, vol.380, issue.15, pp.1450-62, 2019.

. Easl-eortc, Clinical Practice Guidelines: Management of hepatocellular carcinoma, Eur J Cancer. 1 mars, vol.48, issue.5, pp.599-641, 2012.

R. Lencioni and J. M. Llovet, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis. févr, vol.30, issue.1, pp.52-60, 2010.

N. Ganne-carrié and P. Nahon, Hepatocellular carcinoma in the setting of alcohol-related liver disease, J Hepatol. 1 févr, vol.70, issue.2, pp.284-93, 2019.

C. E. Costentin, A. Mourad, P. Lahmek, X. Causse, A. Pariente et al., Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study. Cancer, vol.124, pp.1964-72, 2018.

I. Lee, Y. Chen, Y. Chao, T. Huo, C. Li et al., Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice, Medicine, issue.14, p.94

S. Ogasawara, T. Chiba, Y. Ooka, N. Kanogawa, T. Motoyama et al., Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization, Oncology, vol.87, issue.6, pp.330-371, 2014.

T. Arizumi, K. Ueshima, T. Minami, M. Kono, H. Chishina et al., Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma, Liver Cancer. déc, vol.4, issue.4, pp.253-62, 2015.

C. Liu, G. Xiao, Y. Li, B. Jiang, L. Wen et al., Value of ?-fetoprotein in association with clinicopathological features of hepatocellular carcinoma, World J Gastroenterol WJG. 21 mars, vol.19, issue.11, pp.1811-1820, 2013.

T. Kuzuya, M. Ishigami, T. Ito, Y. Ishizu, T. Honda et al., Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment, Hepatol Res

T. Otsuka, S. Nakashita, K. Yanagita, K. Ario, H. Kawasoe et al., Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib, Diseases. 15 mai, vol.3, issue.2, pp.68-77, 2015.

S. Uchikawa, T. Kawaoka, H. Aikata, K. Kodama, Y. Nishida et al., Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice: Outcomes of HCC patients treated with sorafenib, Hepatol Res. sept, vol.48, issue.10, pp.814-834, 2018.

. Serment-d&apos;hippocrate,

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes